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Abstract— The rapid increase in the number of older people 
with Alzheimer’s disease (AD) and other forms  of dementia 
represents one of the major challenges to the health and social 
care systems. Early detection of AD makes it possible for 
patients to access appropriate services and to benefit from new 
treatments and therapies, as and when they become available. 
The onset of AD starts many years before the clinical  
symptoms become clear. A biomarker that can measure the 
brain changes in this period would be useful  for early diagnosis 
of AD.  Potentially, the electroencephalogram (EEG) can play a 
valuable role in early detection of AD.  Damage in the brain 
due to AD leads to changes in the information processing 
activity of the brain and the EEG which can be quantified as a 
biomarker. The objective  of the study reported in this paper is 
to develop robust EEG-based biomarkers for detecting AD in 
its early stages. We present a new approach to quantify the 
slowing of the EEG, one of the most consistent features at 
different stages of dementia, based on changes in the EEG 
amplitudes (ΔEEGA). The new approach has  sensitivity and 
specificity values of 100% and 88.88%, respectively, and  
outperformed the  Lempel-Ziv Complexity (LZC) approach in 
discriminating between AD and normal subjects. 
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I. INTRODUCTION 
AD is a progressive, neurodegenerative disorder that 
affects cognitive brain functions [1]. The rapid increase in the 
number of people living with AD and other forms of 
dementia represents a significant challenge to our health and 
social care systems and to society. Currently, there are over 
46.8 million individuals with dementia worldwide at an 
annual cost of US$818 billion, and this is projected to reach 
74.7 million by 2030 with an annual  cost of US$ 2 trillion 
[2].  
Early detection of AD is important to enable patients and 
their families to have proper access to available health and 
social care [3]. It also makes it possible for patients to gain 
maximum benefits from  new treatments and therapies, as 
and when they become available, to mitigate against disease  
progression before  irreversible damage is caused to  brain 
cells [4].  
Brain changes caused by AD are believed to start 10 to 20 
years before the clinical symptoms are observed [4]. There is 
a need for a reliable, low-cost, easy to use tool for early 
detection of AD. This requires a biomarker that detects  brain 
changes due to AD in this period. Biomarkers, such as those 
derived from computerized tomography (CT) and magnetic 
resonance imaging (MRI) are useful for AD diagnosis, but 
neuroimaging is expensive, is available only in specialist 
centres,  and it may not be suitable for certain patients (e.g. 
patients with pacemakers or certain  implants [5]).  
Potentially, the EEG can play a valuable role in the early 
detection of AD. Damage to nerve cells/pathways in  the 
brain due to AD causes changes in the information 
processing activity of the brain and the EEG and this can be 
quantified as a biomarker [6][7]. Changes in the information 
processing activity of the brain are thought to be reflected in 
the information content of the EEG [6][7]. In AD patients, 
the EEG is characterized by variations in the complexity 
measures, mean frequency, and in the coherences between 
cortical regions [8].  EEG has a high temporal resolution and 
provides valuable information about brain dynamics in AD 
[9]. Many techniques exist for deriving AD biomarkers from 
the EEG [10]. However, time domain-based approaches are 
potentially one of the most reliable ways to derive robust 
EEG biomarkers  for AD [1][6][11].   
The slowing of the EEG is one of the most consistent 
features at different stages of dementia [11][12][13] and the 
extent of the slowing may be quantified as a  biomarker  of 
AD. In this study, we present a new approach to quantify the 
slowing of the EEG in the time domain by measuring 
changes in the EEG amplitudes. The changes in the 
amplitudes  over time may be viewed as the mean velocity of 
the EEG [14]. The approach is easy to implement and is 
computationally efficient.  
We used the new method to discriminate between AD and 
normal subjects and obtained a sensitivity and specificity 
values of 100% and 88.88%, respectively. We compared the 
performance of the new approach to the LZC method. LZC is 
a nonparametric, non-linear measure of complexity for finite 
length sequences [15]. The LZC approach produces a good 
biomarker for AD detection [16] and is used to analyse brain 
function, brain information transmission, and EEG 
complexity in patients with AD [17]. The new approach 
outperformed the LZC approach using the same datasets. 
The paper is arranged as follows. In Section II, the 
methodology used in the study is described. In Section III, 
the materials (including the datasets and EEG recordings) are 
described. Section IV presents the results and Section V 
concludes the paper. 
II. METHODOLOGY 
In our approach, changes in the amplitudes are used as a 
measure of  the slowing of the EEG.  In particular, the sum of 
the differences between adjacent amplitudes of EEG values 
per second [14] is determined from:   
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where Δx represents  the difference between adjacent 
amplitudes of the EEG in one second and Δt denotes  the 
time interval: 
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where xi  and xi+1 are the current and next EEG amplitude 
values, respectively, and ti and ti+1 represent the 
corresponding times i. 
ΔEEGA is first computed using Equation “(1)” for each 
EEG channel. The mean ΔEEGA for the channel is then 
computed as, 
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where MC is the mean value of ΔEEGA, and N is the number 
of samples for the EEG signal.  
The process of deriving the biomarker is divided into two 
phases – a development phase and a testing phase. In the 
development phase,  two reference feature vectors are created 
from  the mean MC values for all the EEG channels  (one for 
normal and the other for AD groups). In the testing phase, 
one  feature vector is created for each new subject.   
The Euclidean distance measure is then  used to 
discriminate between AD and normal subjects in the 
classification stage, as, 
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where Di is the distance between the reference feature vector 
(V) and the feature vector (Vi) for a new or unknown subject 
i.  
The LZC [15][16][17][18][19] biomarker is used to 
assess the efficiency of the ΔEEGA biomarker.  In the LZC 
computation, the EEG signal is converted to a binary string 
as, 
 






MiEEGif
MiEEGif
ix
)(1
)(0
)(   (5) 
where x(i) is the equivalent binary value of EEG(i), i is the 
index of all values in the EEG signal, and M is the median 
value of each EEG channel (for each EEG channel there is a 
median value). The median value is used to manage the 
outliers. 
The binary string is then scanned from left to right till the 
end to produce new substrings. A complexity counter c(N) is 
the number of the new substrings. The upper bound of c(N) is 
used to normalise c(N) to get an independent value from the 
sequence of length N. The upper bound of c(N) is N/log2(N). 
c(N) is then normalised via b(N) as, 
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where C(N) is the normalised value of the LZC, and b(N) is 
the upper bound of the c(N). The two reference feature 
vectors of the LZC contain the C(N) for all EEG channels 
(one for normal, and the other for AD groups). As before, the 
Euclidean distance measure is used to discriminate between 
AD and normal subjects during classification. 
III. MATERIALS 
Two datasets (A and B) were obtained using a strict 
protocol from Derriford Hospital, Plymouth, U.K. and had 
been collected using normal hospital practices [11]. Dataset 
A consists of 3 Alzheimer’s patients and 8 age-matched 
controls (over 65 years old) all of which  have normal EEGs 
as confirmed by a consultant clinical neurophysiologist. 
Dataset B consists of 24 normal subjects and 17 probable 
AD, which are not perfectly age matched. In the normal 
groups, the mean age is 69.4±11.5 (minimum age is 40 and 
maximum age of  84), and 42% of the subjects are male. In 
the AD group, the mean age is 77.6±10.0 (minimum is 50  
and maximum is 93), and 53% of the subjects are male. 
Dataset A was recorded using the traditional 10-20 
system in a Common Reference Montage (by using the 
average of all channels as the reference) and converted to 
Common Average and Bipolar Montages in software. Dataset 
B was recorded using the modified Maudsley system that is 
similar to the traditional 10-20 system. 
In both datasets, the EEG recordings include various 
states such as awake, hyperventilation, drowsy and alert, with 
periods of eyes closed and open. The sampling rate was 
reduced from 256Hz to 128Hz by averaging two consecutive 
samples for storage reasons. Fig. 1 shows the electrode 
locations in 10–20 system. 
 
Figure 1.  International 10–20 system. 
IV. RESULTS AND DISCUSSIONS 
Following the approach in [11], complete recordings 
including artefacts were used without a priori selection of 
elements ‘suitable’ for analyses. This was to enable us to 
have an idea about the robustness and usefulness of the 
method in practice. Data from a fixed interval (61s to 240s) 
was used to avoid electrical artefacts, which regularly occur 
at the beginning of a record, therefore, give a standard three 
minute data to analyse. 
The datasets were  divided into AD and normal groups. In 
the development phase, 39 subjects from dataset B were used 
(24 normal, and 15 dementia) to create the two reference 
vectors – one for normal group and one for AD group. 
  
Dataset B was used to create the reference feature vectors 
because it is larger than dataset A. Consequently, it has more 
diversity and covered the most problem space. 
In the testing phase, 13 subjects were used (2 dementia 
subjects from dataset A, 3  dementia subjects from dataset B, 
and 8 normal subjects from dataset B) to create a feature 
vector for each subject. 
The p-values using t-test was computed for mean ΔEEGA 
(Mc) between AD and normal groups for each of the 21 
electrodes to determine the most significant channels to be 
used to discriminate between AD and normal groups. 
The Euclidean distances between the reference feature 
vectors and the feature vector of a new or unknown subject is 
then computed.  
We classified a subject as a normal if their vector was 
closer to the reference vector of normal group than AD. 
Otherwise, we classified it as AD. 
In this study, 6 channels of EEG (PZ, FZ, P4, CZ, F8, and 
T6) are used to detect AD by calculating the values of mean 
ΔEEGA for each channel for each subject. These channels 
were selected based on an analysis of the mean ΔEEGA (Mc) 
values for all channels for AD and normal subjects as shown 
in Fig. 3, and Table I. The results show that the ΔEEGA 
values for ADs are lower than for controls. The reduction in 
ΔEEGA values is thought to be due to the slowing in the EEG 
as a result of AD and this is in keeping with the finding in 
other studies [7][20]. 
TABLE I.  MEAN ΔEEGA FOR AD AND NORMAL GROUPS 
Seq. Electrode 
Mean ΔEEGA for 
AD group 
Mean ΔEEGA for 
Normal group 
1 Fp1 32.423 39.458 
2 Fp2 30.717 39.224 
3 F7 30.500 35.485 
4 F3 27.508 29.255 
5 FZ 12.847 27.550 
6 F4 25.528 36.906 
7 F8 29.014 42.259 
8 A1 47.084 38.146 
9 T3 41.691 36.914 
10 C3 25.190 26.612 
11 CZ 12.910 24.082 
12 C4 18.822 29.164 
13 T4 29.282 40.599 
14 A2 35.003 43.115 
15 T5 39.464 45.539 
16 P3 26.635 34.470 
17 PZ 20.170 33.909 
18 P4 23.272 34.804 
19 T6 34.020 45.597 
20 O1 48.508 47.894 
21 O2 41.767 43.528 
 
Fig. 3 and Table II show that PZ channel (parietal lobe) 
has the minimum p-value, followed by FZ (frontal lobe), P4, 
CZ (central lobe), F8, and T6 (temporal lobe). This 
illustrates,  the gradual slowing of brain wave activity due to 
AD, starts from the back of the brain (parietal lobe) towards 
the front (frontal lobe) and from right to the left side and this 
finding is consistent with the other studies 
[13][20][21][22][23]. In addition, occipital lobe is the last 
part of the brain that affected by AD. 
 
Figure 2.  P-values between AD and normal groups. 
 
Figure 3.  Demonstrates the mean ΔEEGA for AD and normal groups. 
TABLE II.  P-VALUES BETWEEN AD AND HEALTHY GROUPS 
Seq. Electrodes P-values 
1 PZ 0.0194 
2 FZ 0.0306 
3 P4 0.0360 
4 CZ 0.0364 
5 F8 0.0733 
6 T6 0.0764 
7 C4 0.1453 
8 T4 0.1586 
9 P3 0.1633 
10 F4 0.1742 
11 Fp2 0.1784 
12 Fp1 0.2119 
13 F7 0.3340 
14 A2 0.3454 
15 T5 0.4139 
16 A1 0.5457 
17 T3 0.6204 
18 F3 0.7709 
19 C3 0.8335 
20 O2 0.8649 
21 O1 0.9597 
 
  
The results of our study are consistent with other studies 
that found out that the slowing of the EEG is a marker for the 
subsequent rate of cognitive and functional decline in AD 
patients [12]. 
The performance of the ΔEEGA biomarker was assessed 
by  calculating its sensitivity, specificity, accuracy, precision 
and error rate. We compared the performance of the new 
approach with that of LZC approach. The results are 
summarised in Table III. It is seen that the new approach 
outperforms the LZC approach. 
TABLE III.  PERFORMANCE RESULTS OF  ΔEEGA, AND LZC 
APPROACHES 
 ΔEEGA LZC 
Sensitivity 100.00 % 36.36 % 
Specificity 88.8888 % 50.00 % 
Accuracy 92.30 % 38.46 % 
Precision 80.00 % 80.00 % 
Error rate  0.0769 0.615 
V. CONCLUSION 
 Our results suggest that changes in EEG amplitudes,   
ΔEEGA  is  a promising  biomarker for AD. As AD subjects  
have significantly lower ΔEEGA values., this  provides an 
effective way to discriminate between AD patients and  
control subjects. Future work will evaluate the new approach   
using  larger EEG datasets. 
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